Pharma Mar Overview
- Founded
-
1986
- Status
-
Public
- Employees
-
477
- Stock Symbol
-
PHM
- Investments
-
1
- Share Price
-
$67.41
- (As of Thursday Closing)
Pharma Mar General Information
Description
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
Contact Information
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
MAD
Primary Office
- Avenida De los Reyes, 1
- Polígono Industrial La Mina
- 28770 Colmenar Viejo
- Spain
+34 918 00 00 00
Pharma Mar Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $67.41 | $68.14 | $52.56 - $98.41 | $1.21B | 18M | 63.2K | $5.84 |
Pharma Mar Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 1,202,658 | 978,458 | 1,424,746 | 949,099 |
| Revenue | 269,183 | 271,729 | 307,732 | 96,070 |
| EBITDA | 121,703 | 122,622 | 177,376 | (10,934) |
| Net Income | 105,293 | 109,787 | 156,467 | (12,738) |
| Total Assets | 421,925 | 417,094 | 406,208 | 139,691 |
| Total Debt | 53,236 | 55,856 | 69,696 | 96,464 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pharma Mar Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharma Mar Patents
Pharma Mar Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3123744-A1 | Anticancer compounds | Pending | 17-Dec-2018 | 0000000000 | |
| AU-2019400736-A1 | Anticancer compounds | Pending | 17-Dec-2018 | 0000000000 | |
| EP-3898613-A1 | Anticancer compounds | Pending | 17-Dec-2018 | 0000000000 | |
| CA-3117268-A1 | Antibody drug conjugates comprising ecteinascidin derivatives | Pending | 25-Oct-2018 | 00000000000 | |
| AU-2019368687-A1 | Antibody drug conjugates comprising ecteinascidin derivatives | Pending | 25-Oct-2018 | A61K47/6803 |
Pharma Mar Executive Team (8)
Pharma Mar Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000 000 0000000000000 | Self | Board Member | 000 0000 |
| 000é 00000-0000 00.0 | Pharma Mar | Board Member & Chief Executive Officer | 000 0000 |
| 0000000000 0000000 | Pharma Mar | Board Member | 000 0000 |
Pharma Mar Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Pharma Mar Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharma Mar Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 02-Nov-2014 | 0000000000 | Biotechnology |